Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV
Kudalkar SN, Ullah I, Bertoletti N, Mandl HK, Cisneros JA, Beloor J, Chan AH, Quijano E, Saltzman WM, Jorgensen WL, Kumar P, Anderson KS. Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Antiviral Research 2019, 167: 110-116. PMID: 31034849, PMCID: PMC6554724, DOI: 10.1016/j.antiviral.2019.04.010.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyBALB/c miceHIV-1C miceT cellsHuman immunodeficiency virus type 1 (HIV-1) infectionImmune deficiency syndrome (AIDS) patientsAntiviral activityNon-nucleoside reverse transcriptase inhibitorNovel non-nucleoside reverse transcriptase inhibitorVirus type 1 infectionDrug-resistant HIV-1Observed serum concentrationsHIV-1 infectionType 1 infectionReverse transcriptase inhibitorNon-nucleoside reversePotent antiviral activityHIV therapeutic agentsSignificant antiviral activitySerum residence timeHIV-1 NNRTIsAntiretroviral therapyClinical benefitSerum concentrations